Spyre Therapeutics (SYRE) Price & Analysis

Compare

473 Followers

SYRE Stock Chart & Stats

$22.47

-$0.27(-1.11%)

At close: Jan 08 4:00 PM EST

$22.47

-$0.27(-1.11%)

Day’s Range― - ―

52-Week Range$10.91 - $40.26

Previous CloseN/A

Volume84.75K

Average Volume (3M)1.03M

Market Cap

$1.72B

Enterprise Value$382.05M

Total Cash (Recent Filing)$526.58M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)2.3

Beta1.56

Next Earnings

Nov 06, 2025

EPS Estimate

-0.76

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.49

Shares Outstanding77,495,550

10 Day Avg. Volume1,783,280

30 Day Avg. Volume1,033,158

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.22

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.72

Forecast

1Y Price Target

$54.33

Price Target Upside141.79% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessSPY001 has demonstrated very favorable pharmacokinetics and pharmacodynamics in its Phase 1 trial.

Growth OpportunitiesConsidering the company’s low enterprise value and multiple avenues for growth, SYRE is seen as a discounted opportunity that can reward the patient investor.

Strategic DevelopmentThe parallel SPY002 (SKYLINE) and SPY072 (SKYWAY) clinical development plan is seen as a smart way to maintain partnering optionality as well as pricing flexibility between different indications.

Bears Say

Clinical Trial FailureThe drug MORF-057 has failed in its subsequent placebo-controlled Ph2b EMERALD-2 UC trial.

Investor SkepticismShort interest in Spyre's stock is relatively high, indicating some level of skepticism among investors.

Spyre Therapeutics News

Spyre Therapeutics 14.86M share Spot Secondary priced at $18.50

The deal priced at below last closing price of $18.92. Jefferies, TD Securities, Leerink, Stifel and Wedbush are...

5d ago

SYRE

Spyre Therapeutics announces common stock offering, no amount given

Spyre Therapeutics (SYRE) announced that it has commenced an underwritten public offering of shares of its common stock...

5d ago

SYRE

Spyre Therapeutics announces poster presentations at UEGW 2025

Spyre Therapeutics (SYRE) announced scientific presentations at the European Gastroenterology Week, UEGW, Congress. “We are excited to share...

13d ago

SYRE

Spyre Therapeutics initiated with a Buy at Deutsche Bank

Deutsche Bank initiated coverage of Spyre Therapeutics (SYRE) with a Buy rating and $43 price target The company’s...

22d ago

SYRE

Spyre Therapeutics Announces Public Stock Offering

Spyre Therapeutics ( ($SYRE) ) has provided an announcement. On October 13, 2025, Spyre Therapeutics entered into an...

3d ago

SYRE

Promising Developments and Strategic Trials Drive Buy Rating for Spyre Therapeutics

BTIG analyst Julian Harrison has maintained their bullish stance on SYRE stock, giving a Buy rating on September...

1M ago

SYRE

Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial

Spyre Therapeutic announced that the first patient has been dosed in its Phase 2 SKYWAY basket trial evaluating...

1M ago

SYRE

Strategic Growth and Innovation Drive Buy Rating for Spyre Therapeutics

Spyre Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from...

1M ago

SYRE

Buy Rating for Spyre Therapeutics: Promising AFFINITY Study Results in Autoimmune Disease Market

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on SYRE stock, giving a Buy rating on...

2M ago

SYRE

Promising Potential of Spyre Therapeutics’ Innovative IBD Treatments Earns Buy Rating

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on SYRE stock, giving a Buy rating on...

2M ago

SYRE

Spyre Therapeutics Reports Q2 2025 Financial Results

Spyre Therapeutics, Inc ( ($SYRE) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

SYRE

Spyre Therapeutics reports Q2 EPS (49c), consensus (71c)

“Spyre is entering a new chapter as we begin to explore the potential of our pipeline to reshape...

2M ago

SYRE

Spyre Therapeutics: A Promising Buy in the IBD Market with Innovative Combination Biologics and Strategic Milestones

In a report released on July 25, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Spyre...

3M ago

SYRE

Positive Phase 2 Data from APGE Bolsters Spyre Therapeutics’ Strategy and Stock Appeal

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on SYRE stock, giving a Buy rating on...

3M ago

SYRE

SYRE FAQ

What was Spyre Therapeutics’s price range in the past 12 months?

Spyre Therapeutics lowest stock price was $10.91 and its highest was $40.26 in the past 12 months.

What is Spyre Therapeutics’s market cap?

Spyre Therapeutics’s market cap is $1.72B.

When is Spyre Therapeutics’s upcoming earnings report date?

Spyre Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 19 days.

How were Spyre Therapeutics’s earnings last quarter?

Spyre Therapeutics released its earnings results on Aug 05, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.754 by $0.264.

Is Spyre Therapeutics overvalued?

According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Spyre Therapeutics pay dividends?

Spyre Therapeutics does not currently pay dividends.

What is Spyre Therapeutics’s EPS estimate?

Spyre Therapeutics’s EPS estimate is -0.76.

How many shares outstanding does Spyre Therapeutics have?

Spyre Therapeutics has 77,495,550 shares outstanding.

What happened to Spyre Therapeutics’s price movement after its last earnings report?

Spyre Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.754. Following the earnings report the stock price went down -5.394%.

Which hedge fund is a major shareholder of Spyre Therapeutics?

Currently, no hedge funds are holding shares in SYRE

Spyre Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-41.00%

Trailing 12-Months

Asset Growth

23.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Spyre Therapeutics

Spyre Therapeutics (SYRE) is a biotechnology company focused on developing innovative treatments for autoimmune diseases. Leveraging cutting-edge research and advanced therapeutic platforms, Spyre Therapeutics aims to address the unmet medical needs in this sector. The company's core products include novel biologics and small molecule drugs designed to modulate the immune system effectively, providing patients with improved outcomes and quality of life.

Spyre Therapeutics (SYRE) Earnings & Revenues

Historic Earnings Reports

SYRE Stock 12 Month Forecast

Average Price Target

$54.33

▲(141.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","42":"$42","71":"$71","27.5":"$27.5","56.5":"$56.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$43.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,27.5,42,56.5,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.63,20.735384615384614,24.840769230769233,28.946153846153848,33.05153846153846,37.15692307692308,41.2623076923077,45.36769230769231,49.47307692307693,53.57846153846154,57.68384615384616,61.78923076923077,65.89461538461539,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.63,19.53,22.43,25.33,28.23,31.130000000000003,34.03,36.93000000000001,39.83,42.730000000000004,45.63,48.53,51.43000000000001,{"y":54.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.63,18.658461538461538,20.686923076923076,22.715384615384615,24.743846153846153,26.77230769230769,28.80076923076923,30.82923076923077,32.857692307692304,34.886153846153846,36.91461538461539,38.94307692307692,40.97153846153846,{"y":43,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >